Clinical trial · Interventional
A Study of Pemetrexed in Small Cell Lung Cancer, Which Has Returned
Phase II Trial of ALIMTA in Relapsed Small Cell Lung Cancer
NCT00191750CI-TRIAL-00000573completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purposes of this study are to determine 1) the safety of pemetrexed and any side effects that might be associated with it 2) whether pemetrexed can help patients with small cell lung cancer live longer 3) whether pemetrexed can make tumors smaller or disappear and for how long and 4) to see if patients feel better while taking pemetrexed
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Small Cell | Small Cell Neuroendocrine Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pemetrexed | Drug | Pemetrexed | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To assess the antitumor activity for patients with both sensitive and refractory small cell lung cancer patients as measured by tumor response rate. To characterize the toxicities of pemetrexed in this patient population
Secondary outcomes (1)
- measure
- To better understand any side effects of pemetrexed
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of small cell lung cancer * One prior treatment with chemotherapy or immunotherapy with greater than 3 weeks since the prior treatment * At least 18 years of age * Estimated life expectancy of at least 12 weeks * Ambulatory and capable of self-care(eg, up and about greater than 50% of waking hours) Exclusion Criteria: * Have received treatment within the last 30 days with a drug that has not received FDA approval for any indication * Less than 2 weeks from radiation therapy * Other serious illness that would compromise the safety of the patient * Most second primary malignancies treated less than 5 years previously
References
Publications (0)
Data not yet available
No reference posted for this study.